Molecular basis of p53 functional inactivation by the leukemic protein MLL-ELL

Molecular and Cellular Biology

Volumn 23, Issue 12, 2003, Pages 4230-4246

  Wiederschain, Dmitri ^a,b   Kawai, Hidehiko ^a   Gu, JiJie ^a   Shilatifard, Ali ^c   Yuan, Zhi Min ^a,b,d  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b HARVARD UNIVERSITY   (United States)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Bldg 1 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEUKEMIC PROTEIN MLL ELL; PROTEIN; PROTEIN CBP; PROTEIN P21; PROTEIN P300; PROTEIN P53; UNCLASSIFIED DRUG;

ACETYLATION; APOPTOSIS; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL NUCLEUS; CELL TRANSFORMATION; CONTROLLED STUDY; ELEVEN LYSINE RICH LEUKEMIA GENE; GENE; GENE FUSION; GENE INACTIVATION; GENE TRANSLOCATION; HUMAN; HUMAN CELL; LEUKEMIA; MALIGNANT TRANSFORMATION; MOLECULAR MECHANICS; MULTIPLE LINEAGE LEUKEMIA GENE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

APOPTOSIS; BLOTTING, WESTERN; CELL LINE; DNA-BINDING PROTEINS; GENES, P53; GENES, TUMOR SUPPRESSOR; GENETIC VECTORS; HUMANS; LEUKEMIA; MICROSCOPY, FLUORESCENCE; MYELOID-LYMPHOID LEUKEMIA PROTEIN; NUCLEAR PROTEINS; ONCOGENE PROTEINS, FUSION; PLASMIDS; PROTEIN STRUCTURE, TERTIARY; TRANS-ACTIVATION (GENETICS); TRANS-ACTIVATORS; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 0037641280     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.23.12.4230-4246.2003     Document Type: Article

References (31)

1. Ayton, P. M., and M. L. Cleary. 2001. Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene 20:5695-5707.
2. Bates, S., and K. H. Vousden. 1999. Mechanisms of p53-mediated apoptosis. Cell Mol. Life Sci. 55:28-37.
3. Butler, L. H., R. Slany, X. Cui, M. L. Cleary, and D. Y. Mason. 1997. The HRX proto-oncogene product is widely expressed in human tissues and localizes to nuclear structures. Blood 89:3361-3370.
4. DiMartino, J. F., T. Miller, P. M. Ayton, T. Landewe, J. L. Hess, M. L. Cleary, and A. Shilatifard. 2000. A carboxy-terminal domain of ELL is required and sufficient for immortalization of myeloid progenitors by MLL-ELL. Blood 96:3887-3893.
5. Downes, M., L. J. Burke, P. J. Bailey, and G. E. Muscat. 1996. Two receptor interaction domains in the corepressor, N-CoR/RIP13, are required for an efficient interaction with Rev-erbA alpha and RVR: physical association is dependent on the E region of the orphan receptors. Nucleic Acids Res. 24:4379-4386.
6. Fleckenstein, D. S., C. C. Uphoff, H. G. Drexler, and H. Quentmeier. 2002. Detection of p53 gene mutations by single strand conformational polymorphism (SSCP) in human acute myeloid leukemia-derived cell lines. Leukoc. Res. 26:207-214.
7. Graf, J., B. Merk, U. Maurer, E. Muller, and L. Bergmann. 2001. Identification of novel polymorphisms in intron 7 of the human p53 gene in acute myeloid leukemia and healthy donors. Leukoc. Lymphoma 41:655-658.
8. Grossman, S. R. 2001. p300/CBP/p53 interaction and regulation of the p53 response. Eur. J. Biochem. 268:2773-2778.
9. Gu, J., D. Chen, J. Rosenblum, R. M. Rubin, and Z. M. Yuan. 2000. Identification of a sequence element from p53 that signals for Mdm2-targeted degradation. Mol. Cell. Biol. 20:1243-1253.
10. Gu, J., L. Nie, D. Wiederschain, and Z. M. Yuan. 2001. Identification of p53 sequence elements that are required for MDM2-mediated nuclear export. Mol. Cell. Biol. 21:8533-8546.
11. Hollstein, M., D. Sidransky, B. Vogelstein, and C. C. Harris. 1991. p53 mutations in human cancers. Science 253:49-53.
12. Jimenez, G. S., M. Nister, J. M. Stommel, M. Beeche, E. A. Barearse, X. Q. Zhang, S. O'Gorman, and G. M. Wahl. 2000. A transactivation-deficient mouse model provides insights into Trp53 regulation and function. Nat. Genet. 26:37-43.
13. Kalejta, R. F., A. D. Brideau, B. W. Banfield, and A. J. Beavis. 1999. An integral membrane green fluorescent protein marker, Us9-GFP, is quantitatively retained in cells during propidium iodide-based cell cycle analysis by flow cytometry. Exp. Cell Res. 248:322-328.
14. Kanda, Y., K. Mitani, M. Kurokawa, T. Yamagata, Y. Yazaki, and H. Hirai. 1998. Overexpression of the MEN/ELL protein, an RNA polymerase II elongation factor, results in transformation of Ratl cells with dependence on the lysine-rich region. J. Biol. Chem. 273:5248-5252.
15. Kanda, Y., K. Mitani, T. Tanaka, K. Tanaka, S. Ogawa, Y. Yazaki, and H. Hirai. 1997. Subcellular localization of the MEN, MLL/MEN and truncated MLL proteins expressed in leukemic cells carrying the t(11;19)(q23;p13.1) translocation. Int. J. Hematol. 66:189-195.
16. Lavau, C., R. T. Luo, C. Du, and M. J. Thirman. 2000. Retrovirus-mediated gene transfer of MLL-ELL transforms primary myeloid progenitors and causes acute myeloid leukemias in mice. Proc. Natl. Acad. Sci. USA 97:10984-10989.
17. Levine, A. J. 1997. p53, the cellular gatekeeper for growth and division. Cell 88:323-331.
18. Lill, N. L., S. R. Grossman, D. Ginsberg, J. DeCaprio, and D. M. Livingston. 1997. Binding and modulation of p53 by p300/CBP coactivators. Nature 387:823-827.
19. Luo, R. T., C. Lavau, C. Du, F. Simone, P. E. Polak, S. Kawamata, and M. J. Thirman. 2001. The elongation domain of ELL is dispensable but its ELL-associated factor I interaction domain is essential for MLL-ELL-induced leukemogenesis. Mol. Cell. Biol. 21:5678-5687.
20. Maki, K., K. Mitani, T. Yamagata, M. Kurokawa, Y. Kanda, Y. Yazaki, and H. Hirai. 1999. Transcriptional inhibition of p53 by the MLL/MEN chimeric protein found in myeloid leukemia. Blood 93:3216-3224.
21. Moorman, A. V., A. Hagemeijer, C. Charrin, H. Rieder, and L. M. Secker-Walker. 1998. The translocations, t(11;19)(q23;p13.1) and t(11;19)(q23; p13.3): a cytogenetic and clinical profile of 53 patients. Leukemia 12:805-810.
22. Seol, W., M. Chung, and D. D. Moore. 1997. Novel receptor interaction and repression domains in the orphan receptor SHP. Mol. Cell. Biol. 17:7126-7131.
23. Shilatifard, A., W. S. Lane, K. W. Jackson, R. C. Conaway, and J. W. Conaway. 1996. An RNA polymerase lI elongation factor encoded by the human ELL gene. Science 271:1873-1876.
24. Shinobu, N., T. Maeda, T. Aso, T. Ito, T. Kondo, K. Koike, and M. Hatakeyama. 1999. Physical interaction and functional antagonism between the RNA polymerase II elongation factor ELL and p53. J. Biol. Chem. 274:17003-17010.
25. So, C. W., and M. L. Cleary. 2002. MLL-AFX requires the transcriptional effector domains of AFX to transform myeloid progenitors and transdominantly interfere with forkhead protein function. Mol. Cell. Biol. 22:6542-6552.
26. Stirewalt, D. L., and J. P. Radich. 2000. Malignancy: tumor suppressor gene aberrations in acute myelogenous leukemia. Hematology 5:15-25.
27. Sweetser, D. A., C. S. Chen, A. A. Blomberg, D. A. Flowers, P. C. Galipeau, M. T. Barrett, N. A. Heerema, J. Buckley, W. G. Woods, I. D. Bernstein, and B. J. Reid. 2001. Loss of heterozygosity in childhood de novo acute myelogenous leukemia. Blood 98:1188-1194.
28. Thirman, M. J., D. A. Levitan, H. Kobayashi, M. C. Simon, and J. D. Rowley. 1994. Cloning of ELL, a gene that fuses to MLL in a t(11;19)(q23;p13.1) in acute myeloid leukemia. Proc. Natl. Acad. Sci. USA 91:12110-12114.
29. Wadgaonkar, R., and T. Collins. 1999. Murine double minute (MDM2) blocks p53-coactivator interaction, a new mechanism for inhibition of p53-dependent gene expression. J. Biol. Chem. 274:13760-13767.
30. Yuan, Z. M., H. Shioya, T. Ishiko, X. Sun, J. Gu, Y. Y. Huang, H. Lu, S. Kharbanda, R. Weichselbaum, and D. Kufe. 1999. p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature 399:814-817.
31. Zhu, Q., G. Wani, M. A. Wani, and A. A. Wani. 2001. Human homologue of yeast Rad23 protein A interacts with p300/cyclic AMP-responsive element binding (CREB)-binding protein to downregulate transcriptional activity of p53. Cancer Res. 61:64-70.